Kura Oncology opened lower at $7.60, compared with its previous close of $7.73. In the last trading session, the stock traded between $7.39 and $7.95. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Kura Oncology is now worth
$ 42.48
Resulting in a loss of
$ 57.52 (57.52%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.29 (-3.78%)
Day High
$7.95
Day Low
$7.39
Day Open
$7.60
Prev Close
$7.73
Volume
23,27,976
1W Return
-2.25%
1M Return
-28.48%
3M Return
-25.02%
6M Return
-21.79%
1Y Return
-30.42%
Fundamentals
Market Cap ($ Mn)
683
PE Ratio
-
PB Ratio
23.22
PEG Ratio
-
ROE
-92.88%
ROCE
-49.61%
EPS (TTM)
$-0.77
Investment Returns
1 Week
-2.25%
1 Month
-28.48%
3 Months
-25.02%
6 Months
-21.79%
9 Months
-5.13%
Financials
Quarterly
All values in $ Mn
53.9
Dec 24
14.1
Mar 25
15.3
Jun 25
20.8
Sep 25
17.3
Dec 25
20.9
Jun 26
Updates
11Nov
Kura Oncology files shelf prospectus; offering size undisclosed
Kura Oncology Inc filed a shelf prospectus with the SEC. The size of the proposed offering is not disclosed. The filing registers securities for a potential future sale.
2 days ago
5Nov
Kura Oncology, Kyowa Kirin to present eight ziftomenib abstracts at ASH 2026
Eight abstracts on ziftomenib accepted for ASH 2026 Annual Meeting. Four oral presentations and four posters to be featured. Data includes first combination results with quizartinib and gilteritinib. Supports ongoing Phase 3 KOMET-017 registrational study.
8 days ago
7Oct
Caspian and Kura to host webcast on diabetes drug data
Caspian and Kura will host an investor webcast on October 13, 2026. The event covers Caspian's formation and KO-7246 preclinical data. KO-7246 is a next-generation menin inhibitor for diabetes treatment. Caspian plans Phase 1 trials to assess β-cell capacity restoration.
1mo ago
29Sep
Caspian, Kura present preclinical data for diabetes drug KO-7246
KO-7246 regenerated functional β-cell mass to 40-90% of healthy levels in Type 1 diabetes models. Drug demonstrated a 3.4-fold increase in β-cell mass in Type 2 diabetes models. Glycemic control persisted for at least one month after treatment stopped. KO-7246 showed superior menin inhibition compared to BMF-219 in biochemical assays.
1mo ago
17Sep
Kura Oncology Q2FY26 Results: Comzifti revenue hits $9.1 million
Comzifti generated $9.1 million in net product revenue in Q2 2026. Company captured majority share of new patient starts in target AML market. Net loss widened to $68.3 million, up from $66.1 million in Q2 2025. Cash position stands at $519 million, funding operations through 2028. Collaboration revenue fell to $11.8 million from $15.3 million year-ago.
1mo ago
8Sep
Kura Oncology appoints Jennifer Fulk as CFO
Jennifer Fulk appointed CFO of Kura Oncology effective September 8, 2026. Fulk reports to CEO Troy Wilson and joins senior leadership team. Brings deep biopharma finance experience in R&D and capital allocation. Company focuses on precision medicines for cancer treatment.
